SignalXSignalX

BCPC BALCHEM CORP

FY2025 10-K
Filed: Feb 20, 2026
Health Care
Chemicals & Allied ProductsSEC EDGAR
BALCHEM CORP Overview

BALCHEM CORP (BCPC) filed its fiscal year 2025 10-K annual report with the SEC on Feb 20, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.

AI Filing Analysis
FY2025 10-K

Business Overview

  • • Core business model: Specialty chemicals and ingredients for health, nutrition, and performance markets
  • • 2026 emphasis on regulatory impact of EPA's EtO Interim Decision affecting sterilization products and applications
+3 more insights

Management Discussion & Analysis

  • • Revenue $1,037M, up 8.8% YoY; Human Nutrition & Health up $59.1M (9.9%), Animal Nutrition & Health up $16.1M (7.5%), Specialty Products up $8.2M (6.2%)
  • • Operating margin 20.2% vs 19.2%, earnings from operations $209.3M, up 14.4%; net earnings $154.8M, up 20.5%
+3 more insights

Risk Factors

  • • Regulatory/legal risk: Tariff and trade changes under the USMCA impacting exports and requiring compliance with evolving export duties and quotas
  • • Geopolitical/macro risk: Supply chain disruption risk from Russia-Ukraine war and Middle East conflict causing material raw material access issues in Europe
+3 more insights

Financial Summary
XBRL

Revenue

$1.0B

Net Income

$155M

Gross Margin

35.7%

Operating Margin

20.2%

Net Margin

14.9%

ROE

12.3%

Total Assets

$1.7B

EPS (Diluted)

$4.75

Operating Cash Flow

$217M

Source: XBRL data from BALCHEM CORP FY2025 10-K filing on SEC EDGAR. All figures in USD.

Get deeper insights on BALCHEM CORP

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.

Try Pro free for 1 month!

Enter SX-8KKYTN at checkout

Limited spots available